ESPEN guidelines on chronic intestinal failure in adults

The guideline authors did not test a single intervention. Instead, they systematically reviewed the entire evidence base for managing chronic intestinal failure (CIF) in adults. The topics covered include:

• Home parenteral nutrition (HPN) management: How to deliver intravenous nutrition safely at home, including catheter care, infusion schedules, and monitoring.
• Parenteral nutrition formulation: What nutrients (carbohydrates, fats, proteins, electrolytes, vitamins, trace elements) to include in the intravenous bags, and in what proportions.
• Intestinal rehabilitation strategies: Medical therapies (e.g., teduglutide, a GLP-2 analogue; growth hormone; glutamine), dietary modifications (e.g., oral rehydration solutions, low-oxalate diets), and non-transplant surgeries (e.g., bowel lengthening procedures like STEP or LILT, segmental reversal of small bowel).
• Management of specific underlying conditions: Short bowel syndrome (SBS), chronic intestinal pseudo-obstruction (CIPO), and radiation enteritis (RE).
• Intestinal transplantation: When to consider it, patient selection criteria, and outcomes.
• Complication prevention and treatment: Catheter-related bloodstream infections (CRBSI), catheter occlusion/thrombosis, intestinal failure-associated liver disease (IFALD), gallbladder sludge/stones, renal failure, and metabolic bone disease.

The outcome measures were not a single endpoint but a broad set of clinical outcomes: survival, quality of life, complication rates (infection, thrombosis, liver disease, bone disease), nutritional status, and ability to wean off parenteral nutrition.

This is a meta-analysis and guideline, not a single study. The evidence base included:

• 623 full papers identified through literature search.
• Only 12% of those were controlled studies (randomised controlled trials or meta-analyses).
• The remaining 88% were case series, cohort studies, expert opinion, or retrospective analyses.
• Patient populations across studies included adults (aged 18+) with chronic intestinal failure due to short bowel syndrome (most common), chronic intestinal pseudo-obstruction, radiation enteritis, and other causes.
• No single sample size applies; individual studies ranged from small case series (n < 20) to larger registry cohorts (n > 500).
• Setting: specialised intestinal failure units, home parenteral nutrition programmes, and transplant centres across Europe, North America, and Australasia.

The guideline used the GRADE system (Grading of Recommendations, Assessment, Development, and Evaluations) to rate the quality of evidence for each recommendation:

• High quality: Further research is very unlikely to change confidence in the estimate of effect.
• Moderate quality: Further research is likely to have an important impact on confidence and may change the estimate.
• Low quality: Further research is very likely to have an important impact on confidence and is likely to change the estimate.
• Very low quality: Any estimate of effect is very uncertain.

For each recommendation, the strength was rated as either strong (the benefits clearly outweigh the risks, or vice versa) or weak (the balance is less certain, or patient values and preferences may vary).

Clinical outcomes were measured using standardised definitions:

• Catheter-related bloodstream infection (CRBSI): Defined by CDC criteria (positive blood culture from a peripheral vein and from the catheter tip, with clinical signs of infection).
• Intestinal failure-associated liver disease (IFALD): Defined by elevated liver enzymes (bilirubin, alkaline phosphatase, ALT, AST) and/or histological changes on liver biopsy.
• Metabolic bone disease: Measured by dual-energy X-ray absorptiometry (DEXA) scan for bone mineral density (BMD), reported as T-scores.
• Quality of life: Measured using validated questionnaires (e.g., SF-36, specific HPN quality-of-life tools).
• Survival: Reported as 1-year, 5-year, and 10-year survival rates from registry data.

Study design: This is a clinical practice guideline developed by a special interest group of ESPEN (European Society for Clinical Nutrition and Metabolism). It is not a single experiment but a systematic synthesis of existing evidence, combined with expert consensus.

Literature search: The authors searched PubMed, EMBASE, and Cochrane databases for papers published up to January 2015. They included studies on adult patients with chronic intestinal failure. The search yielded 623 full papers.

Evidence grading: Each paper was assessed using the GRADE system. The quality of evidence was rated as high, moderate, low, or very low based on study design, risk of bias, inconsistency, indirectness, imprecision, and publication bias.

Consensus process: The guideline authors (a panel of 14 experts from 10 countries) drafted recommendations. These were then submitted to Delphi rounds — a structured process where panel members vote anonymously on each recommendation, with rounds repeated until consensus is reached (defined as >80% agreement). Finally, the recommendations were accepted in an online survey of all ESPEN members.

What this design can and cannot prove:

• Can prove: The guideline provides a comprehensive, expert-consensus framework for managing a rare disease. It identifies areas where evidence exists and where it is lacking. It standardises definitions and treatment approaches across centres.
• Cannot prove: Because 88% of the evidence is from uncontrolled studies, the guideline cannot establish causality for most recommendations. For example, the recommendation to use ethanol lock therapy to prevent CRBSI is based on moderate-quality evidence from a few small RCTs, but the recommendation to use specific PN formulations to prevent IFALD is based on very low-quality evidence from case series. The guideline cannot tell you the exact effect size of any single intervention because the underlying studies are too heterogeneous and underpowered.

Major methodological weaknesses:

• Very low-quality evidence dominates: 51% of recommendations are based on very low-quality evidence, and 39% on low-quality evidence. Only 2% are based on high-quality evidence.
• No meta-analysis of individual patient data: The guideline is a narrative synthesis, not a quantitative meta-analysis. Effect sizes are not pooled across studies.
• Publication bias: Rare diseases like CIF are subject to publication bias — positive results are more likely to be published than negative ones.
• Lack of blinding: Most studies were unblinded, introducing performance and detection bias.
• Short follow-up: Many studies had follow-up of less than 2 years, but CIF is a lifelong condition.

The guideline produced 112 recommendations. Here are the most important ones, with their evidence grades and strengths:

Home Parenteral Nutrition (HPN) Management:

• HPN should be managed by a multidisciplinary team (nutrition specialist, nurse, pharmacist, dietitian, psychologist) — strong recommendation, very low-quality evidence.
• Patients/caregivers should be trained to administer HPN at home — strong recommendation, very low-quality evidence.
• HPN should be infused overnight (10–14 hours) to allow daytime freedom — strong recommendation, very low-quality evidence.

Parenteral Nutrition Formulation:

• Use a lipid emulsion containing a mixture of soybean oil, MCT, olive oil, and fish oil (e.g., SMOFlipid) to reduce the risk of IFALD — weak recommendation, low-quality evidence.
• Provide 0.8–1.5 g/kg/day of amino acids — strong recommendation, very low-quality evidence.
• Provide 20–35 kcal/kg/day of total energy — strong recommendation, very low-quality evidence.
• Monitor and supplement vitamins (A, D, E, K, B12, folate) and trace elements (zinc, copper, selenium, iron) regularly — strong recommendation, very low-quality evidence.

Intestinal Rehabilitation for Short Bowel Syndrome:

• Teduglutide (a GLP-2 analogue) can reduce parenteral nutrition volume by 20–40% in patients with SBS who have a colon in continuity — weak recommendation, moderate-quality evidence.
• Growth hormone and glutamine are not recommended for routine use — strong recommendation, low-quality evidence.
• Oral rehydration solutions (ORS) with sodium 90–120 mmol/L and glucose 20–30 g/L can reduce intravenous fluid needs — strong recommendation, low-quality evidence.
• Surgical bowel lengthening (STEP or LILT) may be considered in selected patients with dilated bowel — weak recommendation, very low-quality evidence.

Catheter-Related Bloodstream Infection (CRBSI):

• Use ethanol lock therapy (70% ethanol, instilled for 2–4 hours daily) to prevent CRBSI — weak recommendation, moderate-quality evidence (from 3 small RCTs showing ~50% reduction in infection rate).
• Treat CRBSI with systemic antibiotics; remove the catheter only if infection persists or if there is septic shock — strong recommendation, low-quality evidence.

Intestinal Failure-Associated Liver Disease (IFALD):

• Monitor liver function tests (bilirubin, ALT, AST, ALP) monthly — strong recommendation, very low-quality evidence.
• If IFALD develops, reduce lipid dose to <1 g/kg/day or switch to a fish-oil-based lipid emulsion — weak recommendation, low-quality evidence.
• Ursodeoxycholic acid (15–20 mg/kg/day) may be considered — weak recommendation, very low-quality evidence.

Intestinal Transplantation:

• Indications for intestinal transplantation include: irreversible IFALD, loss of central venous access (thrombosis of ≥2 major veins), frequent severe CRBSI, and high morbidity from HPN — strong recommendation, low-quality evidence.
• 1-year patient survival after intestinal transplantation is ~80% in experienced centres; 5-year survival is ~50–60% — based on registry data.

Metabolic Bone Disease:

• Monitor bone mineral density (DEXA scan) every 2 years — strong recommendation, very low-quality evidence.
• Supplement vitamin D (400–800 IU/day) and calcium (1000–1500 mg/day) — strong recommendation, very low-quality evidence.

Because this is a guideline, not a single study, effect sizes are not reported as single numbers. However, from the underlying studies:

• Teduglutide: Reduces parenteral nutrition volume by a median of 20–40% (about 3–6 litres per week less) in patients with SBS and a colon in continuity. This translates to 1–2 fewer infusion days per week.
• Ethanol lock therapy: Reduces CRBSI rate from about 2–4 infections per 1000 catheter-days to about 1–2 per 1000 catheter-days — roughly a 50% reduction. In practical terms, this means going from one infection every 6–12 months to one every 12–24 months.
• Fish-oil-based lipid emulsions: In case series, switching from soybean oil to fish oil reversed cholestasis (elevated bilirubin) in 60–80% of children with IFALD. Data in adults are less robust.
• Survival on HPN: 1-year survival is ~90–95%, 5-year survival is ~70–80%, and 10-year survival is ~50–60% in patients with benign disease. Patients with malignant disease have much lower survival (median ~6–12 months).

What the authors acknowledge:

• The rarity of CIF (estimated prevalence 2–5 per million population) makes RCTs extremely difficult to conduct.
• Most recommendations are based on low or very low-quality evidence.
• The guideline is based on expert opinion where evidence is lacking.
• The recommendations may not apply to all healthcare settings (e.g., resource-limited settings).

What a critical reader would note:

• Industry funding: Many of the studies on teduglutide and specialised lipid emulsions were funded by pharmaceutical companies (e.g., Shire, Fresenius Kabi, Baxter). The guideline authors do not declare conflicts of interest in the abstract, but this is a potential source of bias.
• Population limits: The guideline focuses on adults. Children with CIF have different physiology and management needs.
• Self-report bias: Quality-of-life data rely on patient self-report, which can be influenced by psychological factors.
• Lack of blinding: In studies of surgical interventions (e.g., bowel lengthening), blinding is impossible, introducing performance bias.
• Short follow-up: Most studies have follow-up of 1–5 years, but CIF is a lifelong condition. Long-term outcomes (e.g., 20-year survival, late complications) are poorly documented.
• Heterogeneity: The patient population is highly heterogeneous (different underlying diseases, different bowel anatomy, different PN requirements). This makes it difficult to generalise findings.
• No cost-effectiveness analysis: The guideline does not address the cost of treatments (e.g., teduglutide costs ~$100,000–$200,000 per year in the US).

For someone running their own n=1 experiment (note: CIF is a serious medical condition requiring specialist supervision. Do not attempt self-experimentation without medical oversight. These takeaways are for understanding what to discuss with your healthcare team.)

What to test (specific intervention and dose):

• Teduglutide: If you have short bowel syndrome with a colon in continuity, discuss with your doctor whether a trial of teduglutide (0.05 mg/kg/day subcutaneously) is appropriate. It takes 4–8 weeks to see a reduction in PN volume.
• Ethanol lock therapy: If you have recurrent CRBSI, ask about using a 70% ethanol lock (instilled into the catheter for 2–4 hours daily, then flushed out). This is a preventive strategy, not a treatment for active infection.
• Oral rehydration solution (ORS): If you have high stoma output or fluid losses, try an ORS with sodium 90–120 mmol/L and glucose 20–30 g/L (e.g., WHO ORS or a custom recipe). Drink 1–2 litres per day, spaced between meals.
• Dietary modification: If you have SBS with a colon in continuity, try a high-carbohydrate, low-fat diet (50–60% carbohydrate, 20–30% fat) to maximise colonic energy absorption. If you have SBS without a colon, try a high-fat, low-carbohydrate diet to slow transit.

Minimum meaningful duration:

• Teduglutide: 8–12 weeks to assess effect on PN volume.
• Ethanol lock therapy: 3–6 months to assess effect on infection rate (you need enough catheter-days to see a difference).
• ORS or dietary modification: 2–4 weeks to assess effect on fluid balance and stool output.
• Any PN formulation change: 4–8 weeks to assess effect on liver function tests.

What to measure (specific metrics):

• PN volume and frequency: Record the exact volume (in mL) and number of infusions per week. A positive result is a reduction of ≥20% in weekly PN volume.
• Stoma output or stool frequency: Measure in mL per day (for stoma) or number of bowel movements per day. A positive result is a reduction of ≥30%.
• Body weight: Weigh yourself weekly at the same time of day. A positive result is stable weight (±1 kg) while reducing PN.
• Liver function tests: Bilirubin, ALT, AST, ALP — measured monthly. A positive result is a decrease in bilirubin or ALP by ≥20%.
• Catheter-related infections: Record the date, symptoms, and treatment of any suspected infection. A positive result is a reduction in infection rate from >2 per 1000 catheter-days to <1 per 1000 catheter-days.
• Quality of life: Use a validated tool like the SF-36 or a simple